O'pka saratonining EGFR BILAN MOLEKULAR MARKERLARI O'ZBEKISTON
Abstrak
Epidermal o'sish omili retseptorlari tirozin kinaz inhibitörleri (EGFR-TKI), shu jumladan
gefitinib va erlotinib tirozin kinaz domenining qaytariladigan raqobatbardosh inhibitörleridir.
EGFR, uning adenozin-5'-trifosfat (ATP) bilan bog'lanish joyiga bog'lanadi
1
. Somatik mavjudligi
EGFR genidagi mutatsiyalarni faollashtirish, gen nusxalari sonining ko'payishi va o'ziga xos klinik va
morfologik o'simta xususiyatlari etakchi, bu inhibitörlerin yuqori samaradorligi bilan bog'liq
kichik hujayrali bo'lmagan bemorlarda sezilarli o'sma regressiyasi va yaxshilangan klinik natijalarga
o'pka saratoni (NSCLC)
2
References
Seshacharyulu P, Ponnusamy MP, Haridas D, Jain M, Ganti AK, Batra SK.
Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012
Jan;16(1):15-31.
Bethune G, Bethune D, Ridgway N, Xu Z. Epidermal growth factor receptor
(EGFR) in lung cancer: an overview and update. J Thorac Dis. 2010 Mar;2(1):48-51
Jin R, Peng L, Shou J, Wang J, Jin Y, Liang F, Zhao J, Wu M, Li Q, Zhang B, Wu
X, Lan F, Xia L, Yan J, Shao Y, Stebbing J, Shen H, Li W, Xia Y. EGFR-Mutated Squamous Cell
Lung Cancer and Its Association With Outcomes. Front Oncol. 2021 Jun 14;11:680804
Liu J, Xu WY, Ye M, Liu Z, Li C. Genetic Alteration Profiling of Chinese Lung
Adenocarcinoma and Its Effect on Targeted Therapy Efficacy. Front Oncol. 2021 Dec
;11:726547
Clinical Lung Cancer Genome P. Network Genomic M . A Genomics-Based
Classification of Human Lung Tumors. Sci Transl Med (2013) 5(209):209ra153
Osmani L, Askin F, Gabrielson E, Li QK. Current WHO Guidelines and the Critical
Role of Immunohistochemical Markers in the Subclassification of Non-Small Cell Lung
Carcinoma (NSCLC): Moving From Targeted Therapy to Immunotherapy. Semin Cancer Biol
(2018) 52(Pt 1):103–9.
Harrison PT, Vyse S, Huang PH. Rare epidermal growth factor receptor (EGFR)
mutations in non-small cell lung cancer. Semin Cancer Biol. 2020 Apr;61:167-179
You L, Zheng X, Deng D, Pan H, Han W. The benefit of anti-angiogenic therapy in
EGFR exon 21 L858R mutant non-small cell lung cancer patients: a retrospective study. Sci Rep.
Aug 26;12(1):14624
Downloads
Nashr qilingan
Nashr
Bo'lim
License
Copyright (c) 2025 Mirakbarova Zebinisa, Turdikulova Shahlo
This work is licensed under a Creative Commons Attribution 4.0 International License.
(+998)90 142-39-38
Andijon viloyati, Marhamat tumani, Qashqar ko’chasi 189-uy